Abatacept in Immune Checkpoint Inhibitor Myocarditis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 390 participants.
Also called NCT05335928
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 390 participants
- Registry
-
NCT05335928
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT05335928. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-02 (actual); primary completion 2029-04-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Abatacept in Immune Checkpoint Inhibitor Myocarditis
- Acronym
- ATRIUM
- Condition
- Myocarditis Acute
- Condition
- Cancer
- Intervention (Drug)
- Abatacept plus
- Intervention (Drug)
- Placebo
- Lead sponsor
- Massachusetts General Hospital
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct05335928- Content hash
cc436244c2de6986d13e7f103f40069c6d2b2f48989a5d089d520ad964304111